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Objectives. This study sought to characterize functional impair-
ment after simulated ischemia-reperfusion (I/R) or Ca21 bolus in
senescent human myocardium and to determine if age-related
alterations in myocardial concentrations of SERCA2a, phospho-
lamban, or calsequestrin participate in senescent myocardial
dysfunction.
Background. Candidates for elective cardiac interventions are
aging, and an association between age and impairment of relax-
ation has been reported in experimental animals. Function of the
sarcoplasmic reticulum resulting in diastolic dysfunction could be
dysregulated at the level of cytosolic Ca21 uptake by SERCA2a, its
inhibitory subunit (phospholamban), or at the level of Ca21
binding by calsequestrin.
Methods. Human atrial trabeculae from 17 patients (45–75
years old) were suspended in organ baths, field simulated at 1 Hz,
and force development was recorded during I/R (45/120 min).
Trabeculae from an additional 12 patients (53–73 years old) were
exposed to Ca21 bolus (2–3 mmol/L bath concentration). Maxi-
mum 6 dF/dt and the time constant of force decay (tau) were
measured before and after I/R or Ca21 bolus and related to age.
SERCA2a, phospholamban, and calsequestrin from 12 patients
(39–77 years old) were assessed by immunoblot.
Results. Functional results indicated that maximum 6dF/dt
and tau were prolonged in senescent (>60 years) human myocar-
dium after I/R (p < 0.05). Calcium bolus increased the maximum
6dF/dt and decreased tau in younger, but not older patients (p <
0.05). SERCA2a and the ratio of SERCA2a to either phospholam-
ban or calsequestrin were decreased in senescent human myocar-
dium (p < 0.05).
Conclusions. Senescent human myocardium exhibits decreased
myocardial SERCA2a content with age, which may, in part,
explain impaired myocardial function after either I/R or Ca21
exposure.
(J Am Coll Cardiol 1998;32:458–67)
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As an increasing number of aged patients become candidates
for elective cardiac procedures, it is important to determine
whether adult and senescent myocardium respond differently
to common clinical stress (ischemia-reperfusion [IR] injury) or
exogenous calcium (Ca21). Although a decrease in beta-
adrenergic receptors with age may, in part, explain some
senescent myocardial dysfunction (1), many reports have im-
plicated diastolic dysfunction as the most proximal cause of
cardiac failure in humans (2,3). Diastolic dysfunction has been
studied in mouse (4), rat (5–7), and sheep (8). These studies
demonstrated a relationship between age and impairment of
ventricular relaxation (both static and dynamic compliance).
Diastolic dysfunction in humans with heart failure has been
related to age by echocardiography (9,10) and cineangiography
(11).
Calcium dyshomeostasis and I/R have many features in
common (12–14). Intramyocellular calcium ([Ca21]i) overload
due to I/R insult results from ionic dyshomeostasis, sub-
strate deprivation, and impaired energy production processes
(5,12). Increased [Ca21]i associated with dysregulated Ca
21
handling proteins should exacerbate diastolic, and even sys-
tolic, dysfunction. Function of the sarcoplasmic reticulum
may be dysregulated at the level of the sarcoendoplasmic
reticulum Ca21-ATPase (SERCA), its regulatory subunit
(phospholamban), or at the level of Ca21 binding by calse-
questrin (15,16).
Recently, our laboratory (17–25) and others (26–28) have
studied the functioning human myocardial syncitium in vitro.
We hypothesized that systolic and diastolic function are im-
paired in senescent human myocardium exposed to either I/R
or increased extracellular Ca21 due to alterations of Ca21
handling proteins. The purposes of this study were to deter-
mine the relationships between maximum rates of both con-
traction and relaxation before and after I/R or exogenous
Ca21, and relate these parameters to age. Additionally, we
desired to quantify the Ca21 handling proteins most likely to
participate in diastolic dysfunction in the human heart and to
relate their concentrations to age.
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Methods
Isolated atrial trabeculae. Right atrial appendages were
obtained from patients undergoing cardiac surgery for the first
time. All trabeculae and appendages were from patients with
stable cardiac disease. The indication for surgery in all patients
evaluated in this study was ischemic coronary artery disease.
Patients were excluded from the study if they had hemody-
namic instability (mean arterial pressure ,80 mm Hg) within
48 h of cardiopulmonary bypass, atrial dysrhythmias, or right
atrial pressures greater than 10 mm Hg, or evidence of right
atrial hypertrophy. Informed consent was obtained from all
subjects, and the study was approved by the University of
Colorado Health Sciences Center.
Each appendage was placed in oxygenated, modified Ty-
rode’s solution at 4°C. Three to four trabeculae (diameter
,1.0 mm, and length 4–7 mm) were obtained from each
appendage, and suspended vertically in an organ bath and
attached to a force transducer. Each organ bath contained
30 mL modified Tyrode’s solution, which was bubbled (40
mL/min) with a 92.5% O2-7.5% CO2 gas mixture during
normoxia. This mixture provided for a pO2 . 360 mm Hg, a
pCO2 of 38–42 mm Hg, and a buffer pH of 7.35–7.45, which
were checked routinely with an automated blood gas analyzer
(ABL Instruments). Temperature in the organ baths was
maintained at 37.0°C. During the simulated ischemic (SI)
period (SI: consisting of hypoxic, substrate free Tyrode’s
solution with pacing at 3 Hz), which was used only for the I/R
trabeculae, the buffer was changed, the baths were covered to
prevent atmospheric gas exchange, and the gas mixture was
switched to 92.5% N2-7.5% CO2, which produced a pO2
,50 mm Hg. Except during the period of SI, the Tyrode’s
buffer was replaced at 20-minute intervals throughout the
experiment. Trabeculae interrogated using Ca21 bolus alone
remained oxygenated throughout the experiment.
Thirty minutes were allowed after suspension of each
trabecula for recovery. After this time, the trabeculae were
gradually stretched to a resting force of 1 g, which was
determined to be the optimal length-tension for human atrial
trabeculae in our laboratory (17–25), and field stimulated.
Field stimulation occurred with platinum electrodes (Radnoti
Glass, Inc.) at a frequency of 1 Hz. The platinum electrodes
were positioned on either side of each trabecula, and were
driven with stimulators (Grass SD9 stimulator) with 5-msec
pulses at a voltage of 10% above threshold. Isometric contrac-
tile responses were detected by force-displacement transducers
(Grass FT03), and recorded with a computerized preamplifier/
digitizer (MacLab 8; AD Instruments) and a Macintosh com-
puter (Apple Computer). The indices of contractile function
assessed were developed force (DF, g) and resting force (g).
Trabeculae that failed to generate at least 0.25 g of DF were
excluded from the study.
Materials. The modified Tyrode’s solution was prepared
daily with de-ionized distilled water (ddH2O) and consisted of
(in mmol/L): D-glucose, 5.0; CaCl2, 2.0; NaCl, 118.0; KCl, 4.0;
MgSO4z7 H2O, 1.2; NaHCO3, 25.0; and NaH2PO4, 1.2. All
reagents were from Sigma Chemical Company. In the
substrate-free Tyrode’s solution used during simulated isch-
emia, choline (7.0 mmol/L) was added to maintain constant
osmolarity.
Experimental design. To investigate the role of I/R on
human myocardial systolic and diastolic function, a total of 17
atrial appendages were obtained from patients with chronic
ischemic heart disease (mean age 60.4 6 2.6 years, 15 males
and 2 females). No trabeculae were excluded from analysis.
Ischemia reperfusion trabeculae were subjected to a 90-minute
equilibration period to allow for plateau and stabilization of
developed force, and subsequently these experiments were
conducted for 165 minutes. I/R trabeculae were challenged
with a 45-minute period of SI, which consisted of hypoxic,
substrate-free Tyrode’s solution with pacing at 3 Hz, followed
by 120 minutes of reoxygenation with normoxic Tyrode’s
solution with pacing at 1 Hz.
Twelve patients (mean age 61.2 6 2.0 years, 9 males and 3
females), also with chronic ischemic heart disease, provided
atrial appendages to investigate the effect of Ca21 bolus on
cardiac function. Again, no trabeculae were excluded from
analysis. Calcium-challenged trabeculae were also equilibrated
for 90 minutes, then bath Ca21 concentration was increased to
3.0 mmol/L from 2.0 mmol/L. At end of either protocol, all
trabeculae were removed from the organ baths, weighed, and
measured.
Calcium dose-response data previously determined in our
laboratory indicated that 3.0 mmol/L represented approxi-
mately the inotropic mid-point, corresponding to one-half
maximal inotropic response to Ca21 (20). However, we also
wanted to determine if senior myocardium responded any
differently to the 3.0 mmol/L Ca21 dose than junior myocar-
dium, in terms of absolute developed force. Data were strati-
fied by age and revealed no difference in myocardial sensitivity
to exogenous Ca21. These Ca21 dose-response data (n 5 6
each junior [age #60 years] and senior [age .60 years]
myocardium) were obtained by determining the change in
developed force (in mg) relative to the baseline-developed
Abbreviations and Acronyms
SERCA2a 5 sarcoendoplasmic reticulum Ca21-ATPase
I/R 5 ischemia-reperfusion
T 5 tau, the time constant of force decay
SI 5 simulated ischemia
[Ca21]i 5 intramyocellular calcium
CAD 5 coronary artery disease
HTN 5 hypertension
IDDM 5 insulin-dependent diabetes mellitus
NIDDM 5 non–insulin-dependent diabetes mellitus
GERD 5 gastro-esophageal reflux disease
COPD 5 chronic obstructive pulmonary disease
CHF 5 congestive heart failure
LAD 5 left anterior descending coronary artery
RCA 5 right coronary artery
Cx 5 circumflex coronary artery
LVEF 5 left ventricular ejection fraction
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force (%BDF). The experimental protocols are depicted in
Figure 1. In addition, control trabeculae were equilibrated for
90 minutes and perfused with normoxic Tyrode’s with pacing at
1 Hz for 180 minutes to ensure model stability. Each trabecu-
lae was used in only a single experiment and multiple trabec-
ulae from the same patient were each used in a different
protocol. Trabecular baseline tissue characteristics are pre-
sented in Table 1.
We measured maximum 1dF/dt during contraction and
2dF/dt during relaxation before and after I/R injury or Ca21
bolus for each respective trabeculae. The maximum slope of
the contraction or the relaxation phase was located and
averaged over approximately 120 beats using Matlab software
(The Math Works, Inc.). This data analysis resulted in an
averaged maximum slope, which was compared with the initial
averaged maximum slope. The functional results are expressed
as fraction of baseline value for the I/R trabeculae, or fraction
over baseline for the Ca21-challenged trabeculae. Also, we
computed T (tau), which is the time constant of force decay
(8,29–31) before and after I/R injury or Ca21 bolus for each
respective trabeculae at the same time intervals used in the
calculation of 6dF/dt using Matlab software. We determined
tau according to the method of Weiss et al. (31), who deter-
mined the time constant by fitting the monoexponential model
to force decay data after the time of maximum negative 2dF/dt
to a point 5% above the minimum diastolic developed force.
Relaxation force data were fit to the following exponential
equation: F(t) 5 aze(2t/T), where a is a constant, t is the time
during the peak 2dF/dt to a point 5% above the minimum
diastolic force development, and T is tau, the time constant of
force decay.
Preparation of myocardial tissue homogenates. Approxi-
mately 250 mg of human atrial appendage, from which a
trabeculae was harvested for use in the I/R, Ca21 challenge
experiments, or in some cases other protocols, was homoge-
nized in a tenfold volume of 20 mmol/L Na-Hepes, pH 7.4, for
4 3 15 s using the Tekmar tissumizer (Tekmar Company), at
4°C. The protein concentration was determined in triplicate
according to Lowry et al. (32). The protein per gram net weight
was calculated from the protein concentration of the homog-
enates. The yield of protein per gram wet weight of tissue was
191.5 6 29.7 mg/g in the youngest four patients, 176.0 6 6.7
mg/g in the middle four patients, and 160.7 6 18.7 mg/g in the
oldest four patients. Aliquots of the homogenates were frozen
in liquid nitrogen and stored at 270°C until use.
Western blot analysis. Tissue homogenates were solubi-
lized in 2% sodium dodecyl sulfate (SDS), 5% 2-beta-
mercaptoethanol, 10% glycerol, 0.00125% bromophenol blue,
and 0.0625 mol/L Tris-Cl, pH 6.8. Lysis was performed for
5 min at 95°C to dissociate the pentameric form of phospho-
lamban into subunits and de-aggregate myocellular proteins.
Samples were subjected to SDS-PAGE using the Laemmli
buffer system (33) in a Mini-Protean II dual slab cell (Bio-Rad
Ltd.). Electrophoresis was performed until complete elution of
the dye front. Proteins were transferred to nitrocellulose in a
mini Trans-Blot Transfer Cell (Bio-Rad Ltd.) according to the
procedure of Towbin with the modification that SDS was
included in the transfer buffer (25 mmol/L Tris, 192 mmol/L
glycine, 0.0375% SDS, and 20% [vol/vol] methanol, pH 8.3).
The transfer was carried out at room temperature for 1 h at a
constant voltage setting of 100 V. Transfer was checked by
staining the blots in Ponceau S solution (Sigma Ltd.) and
staining of the remaining polyacrylamide gels in Coomassie
brilliant blue G (Sigma Ltd.). The blots were blocked in 5%
nonfat milk diluted in phosphate-buffered saline (PBS) (40
mmol/L Na2HPO4, 8 mmol/L NaH2PO4, 154 mmol/L NaCl,
pH 7.4) for 1 h at room temperature. The blots were washed
three times for 10 min with fresh PBS. The blots were
incubated with the appropriate primary antibody to SERCA2a,
phospholamban, or calreticulin (Affinity Bioreagents) in solu-
tion, diluted in TPBS (40 mmol/L Na2HPO4, 8 mmol/L
NaH2PO4, 154 mmol/L NaCl, 0.1% Tween-20, pH 7.4) and 5%
nonfat milk overnight at 4°C. The blots were washed three
times for 10 min in TPBS and then incubated in the secondary
anti–mouse horseradish peroxidase–conjugated antibody solu-
tion (Amersham Life Science) diluted in the same buffer as
above for 1 h at room temperature. The blots were again
washed two times for 10 min in TPBS and two times for 10 min
in PBS, incubated in enhanced chemiluminescence (ECL)-
detection reagents (Bio-Rad Ltd.) for 1 min, and exposed to an
X-OMAT AR X-ray film (Kodak, Inc.) for 30 s to 10 min.
Western blot analysis of SERCA2a, monomeric phospholam-
ban, pentameric phospholamban, and calsequestrin were each
performed using trabeculae from 12 patients (aged 39–77
years). Patient demographic data for all myocardium evaluated
in the functional studies as well as the protein quantification
study are provided in Table 2.
Figure 1. Experimental protocols. All experiments were preceded by a
90-min period that allowed for stabilization of developed force.
Simulated ischemia refers to incubation of trabeculae in substrate free,
hypoxic Tyrode’s solution while pacing at 3 Hz. Normoxic perfusion
and reperfusion refer to incubation of trabeculae in oxygenated
Tyrode’s with substrate and pacing at 1 Hz. Ca21 and wash indicate
Ca21 concentration changes to from 2.0 to 3.0 mmol/L and back to 2.0
mmol/L, respectively.
Table 1. Human Myocardial Baseline Tissue Characteristics
Group
Systolic Force
(mg)
Resting Force
(mg)
Cross-Sectional
Area (mm2)
I/R (n 5 17) 897 6 113 1,008 6 7 0.49 6 0.10
Ca21 (n 5 12) 661 6 143 1,016 6 11 0.53 6 0.12
Values are mean 6 SEM.
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Quantification of immunoreactive bands. The band densi-
ties were evaluated by densitometric scanning using a laser
scanning densitometer. Relative protein quantitation was per-
formed by normalization of all patients for a given protein to
the absorbance value computed for a defined reference heart
(the 39-year old patient) to promote standardization. Results
were expressed graphically as linear regression of each protein
versus age.
Statistical analysis. Differences in preservation of systolic
and diastolic function as well as myocardial protein content
were assessed using linear regression versus age (95% confi-
dence bands were computed). Also, differences in myocardial
protein content were assessed between junior and senior
cohorts by ANOVA (Bonferroni/Dunn). p , 0.05 was ac-
cepted to represent significance. Regression coefficient (R)
was computed for each linear regression. Differences in tau
between junior and senior myocardium were compared using
the paired t-test.
Results
Baseline Functional Data. Linear regression of 6dF/dt at
baseline for either the I/R trabeculae or the Ca21-challenged
trabeculae revealed no relationship to age (each p . 0.05).
However, when posttreatment functional results were com-
pared with baseline values, significant relationships to age were
demonstrated.
I/R Trabeculae. Systolic function, as assessed by remaining
1dF/dt after I/R (fraction of baseline) for each trabeculae
versus age using linear regression, revealed the relationship
depicted in Figure 2A. The equation of the regression line was
Y 5 20.01X 1 0.928. R 5 0.85, p , 0.0001. The negative slope
indicated that older patients did not preserve their rates of
contraction after I/R as well as younger patients. For diastolic
function, remaining 2dF/dt after I/R (fraction of baseline) for
each trabeculae versus age using linear regression revealed the
relationship depicted in Figure 2B. The equation of the
Table 2. Demographic Characteristics
Age (Years) Diseases Medications Coronary Angio LVEF
39 CAD heparin/restoril/vicodin 90% L main normal
45 CAD/depression/HTN/GERD benazapril/atenolol/zoloft/clonepine/tagamet 100% LAD/60% RCA/50% Cx 47%
47 CAD/GERD famotidine/isosorbide 95% LAD/50% RCA/50% Cx 72%
48 CAD/IDDM/HTN/hypercholesterolemia/
hypothyroidism
atenolol/felodipine/insulin/levothyroxine/
isosorbide/pravastatin/cholestyramine
80% LAD/75% RCA/70% Cx 54%
48 CAD/HTN atenolol/aspirin 100% LAD/70% RCA/40% Cx 45%
49 CAD/HTN/GERD verapamil/lisinopril/famotidine/zocor lopressor 100% LAD/90% RCA/80% Cx 26%
50 CAD pepcid/restoril 50% LAD/60% RCA/50% Cx normal
50 HTN atenolol/aspirin/heparin/isordil 70% LAD/95% RCA/50% Cx 61%
51 CAD none 100% LAD/70% RCA/70% Cx 60%
53 CAD/HTN atenolol 80% LAD/40% RCA/30% Cx 71%
53 CAD/HTN metaprolol/captopril 80% LAD/100% RCA/30% Cx 45%
55 CAD/NIDDM/GERD NTG/metaprolol/cimetidine/glyburide 80% LAD/400% RCA/30% Cx 71%
56 CAD/CHF/hypercholesterolemia HCTZ/benazapril/isorbide/pravastatin 75% LAD/50% RCA/50% Cx 55%
59 CAD/NIDDM/gout/HTN felodipine/metaprolol/benazapril/
cholchicine/glyburide
70% LAD/100% LAD/50% Cx normal
60 CAD/Hypothyroidism/NIDDM glucophage/zestril/synthroid/glucotrolzocor 90% LAD/90% RCA/90% Cx 45%
60 CAD/HTN/NIDDM/GERD lasix/zocor/heparin/metaprolol/fosinopril/
indur/ASA/axid/glucophage
90% LAD/50% RCA/70% Cx 60%
61 CAD/HTN/GERD captopril/omeprazole/metaprolol/NTG/sucralafate 90% LAD/50% RCA/70% Cx normal
62 CAD/HTN isorbide/vasotec/atenolol/amlodipine 70% LAD/90% RCA/50% Cx 50%
63 CAD/HTN/GERD/COPD aspirin/amlodipine/axid/isordil/atrovent 50% LAD/100% RCA/30% Cx 60%
63 CAD/hypercholesterolemia benazapril/pravastatin/nitroglycerin 90% LAD/40% RCA/70% Cx normal
63 CAD/HTN/hypercholesterolemia vasotec/zocor/clonidine/ASA/lasix/prednisone 40% LAD/70% RCA/40% Cx normal
64 CAD/HTN/GERD/hypercholesterolemia atenolol/isorbide/gemfibrozil/tagamet 90% LAD/100% RCA/50% Cx normal
65 CAD/HTN/GERD atenolol/cimetidine 80% LAD/95% RCA/70% Cx 35%
66 CAD/GERD/HTN/CHF benazapril/omeprazole/diltiazem/prazosin/lasix/Fe 90% LAD/80% RCA/80% Cx 40%
66 CAD/HTN captopril 80% LAD/60% RCA/80% Cx 69%
69 CAD none 70% LAD/100% RCA/90% Cx 59%
69 CAD/HTN/hypercholesterolemia atenolol/pravastatin 95% LAD/70% RCA/100% Cx normal
71 CAD/HTN verapamil/testosterone 50% LAD/80% RCA/75% Cx normal
72 CAD/IDDM/hypercholesterolemia/HTN pravastatin/desipramine/insulin/atenolol 100% LAD/50% RCA/80% Cx normal
73 CAD/GERD/HTN/NIDDM paxil/ticlid/cisapride/pepcid/atrovent/
glucotrol/propranolol/NTG
90% LAD/90% RCA/60% Cx 60%
73 CAD/hypercholesterolemia NTG/ASA/heparin/zocor 50% LAD/80% RCA/75% Cx normal
74 CAD/NIDDM glipizide/isordil 60% LAD/80% RCA/90% Cx 44%
75 CAD/NIDDM/gout heparin/allopurinol/lasix 80% LAD/60% Cx 55%
77 CAD/HTN potassium/metaprolol 95% LAD/100% RCA/50% Cx normal
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regression line is Y 5 20.0096X 1 0.988. R 5 0.61, p , 0.01.
Again, the negative slope revealed that older patients did not
preserve their rates of relaxation after I/R as well as younger
patients. The time constant of force decay (tau) was calculated
before and after I/R to further define the diastolic phase of the
myocardial cycle. The time constant of force decay was in-
creased, indicating prolonged relaxation, in both junior and
senior myocardium (17.7 6 2.9 vs. 21.7 6 2.7 ms and 14.7 6 1.2
vs. 18.8 6 1.2 ms respectively; both p , 0.05 vs. tau pre-I/R).
Tau pre-I/R did not differ between junior and senior myocar-
dium (p . 0.05) (Table 3).
Ca21-challenged Trabeculae. To determine if Ca21 sensi-
tivity differed between junior and senior myocardium, inotrop-
ic response was measured in terms of increase over baseline-
developed force. Junior and senior myocardium did not differ
in terms of Ca21 sensitivity (Fig. 3A). Systolic function (1dF/
dt) after Ca21 bolus (expressed as increase over baseline) for
each trabeculae versus age revealed the relationship depicted
in Figure 3B. The equation of the linear regression line is Y 5
20.022X 1 1.573. R 5 0.85, p , 0.0004. This regression
revealed that younger patients can increase their maximum
rates of systolic contraction after Ca21 bolus, in contrast to
older patients, whose maximum systolic rates appear nearly
fixed. Diastolic function (2dF/dt) after Ca21 bolus for each
trabeculae versus age revealed the relationship depicted in
Figure 3C. The equation of the regression line is Y 5
20.024X 1 1.712, R 5 0.84, p , 0.0007. Younger patients
were capable of increasing their maximum rates of relaxation
in contrast to older patients, whose relaxation rates were nearly
constant. The time constant of force decay was decreased,
indicating a shorter relaxation phase, in junior myocardium
(15.2 6 1.1 vs. 18.5 6 2.1 ms; p , 0.05 vs. tau pre-Ca21), but
not senior myocardium (15.8 6 0.7 vs. 16.7 6 0.9 ms; p . 0.05
vs. tau pre-Ca21). Tau pre-Ca21 did not differ between junior
and senior myocardium (p . 0.05) (Table 3). There were no
changes in resting force (diastolic tension) before, during, or
after Ca21 infusion.
Sarcoplasmic reticulum Ca21 handling proteins. Immuno-
blot against the sarcoendoplasmic reticulum Ca21-ATPase
(SERCA2a), its inhibitory subunit phospholamban, and calse-
questrin versus increasing age is shown in Figure 4. Protein
levels of SERCA2a, pentameric phospholamban, and mono-
meric phospholamban were decreased (p , 0.003, p , 0.003,
and p , 0.03, respectively) in senescent myocardium as
assessed by linear regression (Figure 5). Protein levels of
calsequestrin were unaffected by age when analyzed by linear
regression (p . 0.05). Division of the patients into junior and
senior cohorts revealed that SERCA2a and pentameric phos-
pholamban were decreased (p , 0.001, and p , 0.002, re-
spectively) in senior versus junior myocardium (Fig. 6, A and
B). Calsequestrin and phospholamban were unaffected by age
(both p . 0.05, and p . 0.05) (Fig. 6, C and D). Calsequestrin
has been determined to remain relatively constant over disease
states (15), and thus normalization of SERCA2a to calseques-
trin was performed to determine if the loss of SERCA2a
simply represented a loss of all Ca21 handling proteins. The
ratio of SERCA2a to calsequestrin was decreased in senescent
myocardium (p , 0.007) (Fig. 7A). As phospholamban (mo-
Figure 2. A) Maximum rate of systolic contraction after simulated
ischemia reperfusion injury (as measured by the ratio of 1dF/dt before
and after I/R) was better preserved in the younger versus older
patients. B) Maximum rate of diastolic relaxation or compliance after
simulated ischemia reperfusion injury (as measured by the ratio of
2dF/dt before and after I/R) was better preserved in the younger
versus the older patients. Dotted lines depict the 95% confidence
limits.
Table 3. Time Constant of Force Decay (Tau)
Tau
Junior Myocardium Senior Myocardium
Pre I/R 17.7 6 2.9 n 5 7 patients 14.7 6 1.2 n 5 10 patients
Post I/R 21.7 6 2.7* 18.8 6 1.2*
Pre Ca21 18.5 6 2.1 n 5 6 patients 16.7 6 0.9 n 5 6 patients
Post Ca21 15.2 6 1.1† 15.8 6 0.7‡
Values are mean 6 SEM (ms). *p , 0.05 vs. pre-I/R; †p , 0.05 vs. pre-Ca21;
‡p . 0.05 vs. pre-Ca21.
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nomeric) inhibits SERCA2a (34,35), perhaps SERCA2a activ-
ity is influenced by the ratio of these two proteins (15). Indeed,
the ratio of SERCA2a to phospholamban was decreased in the
senescent myocardium (p , 0.035) (Fig. 7B).
Discussion
The results of the present study demonstrate that: 1) prior
to simulated ischemia, systolic and diastolic function in human
myocardium are not related to age; 2) simulated ischemia
reperfusion causes a decrease in the maximum rate of myocar-
dial contraction and relaxation in all patients; 3) simulated
ischemia reperfusion results in a relatively greater impairment
of maximum positive and negative dF/dt in senescent human
myocardium; 4) senescent myocardium is relatively unrespon-
Figure 3. A) Inotropic response to 3.0 mmol/L Ca21 concentration.
Percent baseline developed force (%BDF) versus age group (se-
nior, .60 years; junior, #60 years) is depicted. Increase in devel-
oped force after exposure to exogenous Ca21 did not differ between
senior and junior myocardium (p . 0.05). B) Maximum rate of
systolic contraction after Ca21 bolus (as measured by the ratio of
1dF/dt before and after Ca21 bolus) was increased in the younger
patients; however, older patients were not able to increase their
rates of systolic contraction. C) Maximum rate of diastolic relax-
ation or compliance after Ca21 bolus (as measured by the ratio of
2dF/dt before and after Ca21 bolus) was increased in the younger
patients; however, older patients were not able to increase their
rates of diastolic relaxation. Dotted lines depict the 95% confidence
limits.
Figure 4. Immunoblot against SERC2a (110 kD), calsequestrin (63
kD), pentameric phospholamban (25 kD), and monomeric phospho-
lamban (25 kD). Samples were each immunoprecipitated with anti-
SERC2a, calsequestrin, or phospholamban selective antibodies, sepa-
rated by SDS-PAGE on a 4–20% acrylamide gel, and then visualized
by autoradiography. With increasing age, protein concentration of
SERC2a and pentameric phospholamban decrease with age, while
calsequestrin and monomeric phospholamban remain relatively con-
stant.
Figure 5. Protein concentration of SERCA2a (normalized to youngest
patient) assessed by Western blot. SERCA2a protein content de-
creased with increasing age by linear regression (p , 0.003). Dotted
lines depict the 95% confidence limits.
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sive to exogenous Ca21; 5) SERCA2a, pentameric phospho-
lamban, and monomeric phospholamban protein contents are
decreased in senescent human myocardium; and 6) the ratios
of SERCA2a to calsequestrin or phospholamban were de-
creased in senescent human myocardium. These results sug-
gest that the aging impairs Ca21 handling in the human
myocardium.
I/R decreases rates of contraction and relaxation. In the
present study, no correlation between age and preischemic
systolic or diastolic function was observed. This finding is in
concert with a study demonstrating normal human myocardial
Ca21 uptake in both dilated cardiomyopathy and nonfailing
hearts in an unpreturbed state (36). However, a relationship to
age was demonstrated when these functional indices were
measured after I/R and normalized them to their preischemic
values. Systolic function is commonly clinically expressed as
ejection fraction calculated from ventriculography, echocardi-
ography, and nuclear medicine studies. Patient morbidity and
survival have successfully been predicted based on these
parameters (37–40). Diastolic dysfunction as a common cause
of heart failure in humans has only recently been appreciated
(41,42), and may represent a prevalent early cause of cardiac
failure (2,3,43). Diastolic dysfunction has been studied in many
species (2–8), and a relationship between age and impairment
of relaxation has been suggested. Diastolic dysfunction has also
been studied clinically in humans, utilizing Doppler echocar-
diography and contrast ventriculography (9–11). Perhaps not
surprisingly, there was a significant correlation between dia-
stolic relaxation time and age in 75 patients with coronary
artery disease (10). In a subsequent study by the same authors,
enrolling 85 patients with 56 healthy volunteers as controls, an
age-related impairment of relaxation was again reported.
However, this same study concluded that Doppler echocardi-
ography may be imprecise when used to diagnose left ventric-
ular diastolic function in patients older than 65 years (9).
Ventriculography has recently been used to evaluate systolic
and diastolic function in “senior” (mean age 5 46 years) and
“elderly” (mean age 5 70 years) patients with aortic stenosis.
The authors found no relationship to age for systolic function,
but found a linear correlation between age and myocardial
stiffness in their patients with aortic stenosis (11). In the
present study, it is likely that the I/R stimulus served to
magnify existing differences between patients, resulting in a
measurable differential response to I/R in younger versus older
patients.
Ischemia reperfusion results in energy substrate depriva-
tion, cellular edema, Ca21 overload, activation of autolytic
enzymes, disruption of membranes, and mitochondrial dys-
function (12,22,26–28,44–47). All of the above likely contrib-
ute to postischemic Ca21 dyshomeostasis. Indeed, elevated
[Ca21]i has been related to postischemic mechanical dysfunc-
tion in both reversibly and irreversibly injured myocardium
(48). The postischemic elevation of [Ca21]i is likely due to
Figure 6. Protein concentration of: A) SERCA2a, B) calsequestrin, C)
pentameric phospholamban, and D) monomeric phospholamban, be-
tween junior (#60 years) and senior (.60 years). SERCA2a and
pentameric phospholamban were both decreased in the senior myo-
cardium (*p . 0.05 vs. junior age group). Calsequestrin and mono-
meric phospholamban did not differ between these two groups (p .
0.05).
Figure 7. A) SERCA2a normalized to calsequestrin protein levels
revealed that the decrease in SERCA2a protein did not reflect a
general loss of myocardial Ca21 handling proteins with age (*p , 0.05
vs. junior age group), and B) SERCA2a normalized to monomeric
phospholamban protein levels as an assessment of SERCA2a activity
revealed that SERCA2a activity was decreased with age (*p , 0.05 vs.
junior age group).
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impaired [Ca21]i sequestration and/or extrusion (49,50). Our
results suggest that these processes are impaired in senescent
myocardium, and perhaps older patients might not be able to
tolerate a clinical I/R stimulus as well as younger patients.
Since the compromised diastolic function observed in older
myocardium in the present study implies reduced myocardial
compliance, older patients may require higher filling pressures
to optimize cardiac output due to their impaired myocardial
pressure-volume relationships.
Exogenous Ca21 and senescent myocardium. In the
present study, we found that younger patients were able to
increase both their rates of contraction and relaxation after
Ca21 bolus. However, senescent patients possessed nearly
fixed rates of contraction and relaxation when treated with
Ca21. Precise cardiac myocyte [Ca21]i regulation is paramount
for efficient systolic and diastolic function. The inotropic
effects of extracellular Ca21 are believed to be the result of a
“Ca21 trigger” of intracellular sarcoplasmic reticulum (SR)
Ca21 release during depolarization (Ca21-induced Ca21 re-
lease) (51). Transient increases in [Ca21]i are required for
excitation-contraction coupling in the heart (51,52). Calcium
binding of troponin C results in a conformational change that
enhances actin-myosin cross-linkage. Increased extracellular
Ca21 further enhances actin-myosin interaction, resulting in
inotropy. Intracellular Ca21 sequestration via the SERCA2a
results in a fall in [Ca21]i, causing dissociation of [Ca
21]i from
the contractile apparatus (12). Thus, the functional responses
to increased extracellular Ca21 or I/R observed in the present
study in senescent myocardium may be due to impaired or
downregulated Ca21 uptake proteins (i.e., SERCA2a).
SERCA2a is decreased in senescent human myocardium.
We observed a relative decrease of the myocardial Ca21
handling protein SERCA2a, monomeric phospholamban, and
pentameric phospholamban protein content in older myocar-
dium when analyzed by linear regression. Calsequestrin levels
remained relatively unchanged in relation to age. This manu-
script represents the first report that SERCA2a is decreased in
the aged human heart. Others have previously postulated that
the extraordinary [Ca21]i load induced by I/R may be improp-
erly handled due to downregulation of the SERCA protein in
aged laboratory animal, and in ischemic or failing human
myocardium (6,15,53–61). Decreased SERCA2a may result in
an inability to sequester cytosolic Ca21 after a depolarization,
leading to diastolic dysfunction. We elected to quantify the
differences in protein expression between the myocardial pro-
teins SERCA2a, phospholamban, and calsequestrin between
younger and older patients for the following reasons: 1)
protein expression, rather than mRNA content, likely corre-
lates more closely with function; 2) it is possible that mRNA
transcription is independently downregulated with age; 3)
studies have demonstrated that in disease, SERCA2a mRNA
content and SERCA2a protein content may not always change
together or to the same magnitude (62,63); 4) SERCA2a is the
predominant isoform expressed in adult myocardium (56); and
5) SERCA2a protein content has been successfully used to
differentiate normal from dilated cardiomyopathic human
heart (15). Cardiac SERCA2a mRNA was decreased in human
myocardium from patients undergoing heart transplant when
compared with organ donor heart (15,55,57).
SERCA2a mRNA is decreased in both senescent rat (6)
and rat exposed to cardiac overload (54). SERCA2a activity in
porcine myocardium was found to be downregulated after the
I/R injury of cardiopulmonary bypass, and appeared better
preserved using warm blood cardioplegia rather than crystal-
loid (61). Phospholamban (the inhibitory subunit of SERCA)
mRNA expression also appears to be correlated with age in rat
(neonatal vs. adult) (64) and heart failure (15). It is the
nonphosphorylated monomeric phospholamban that inhibits
SERCA2a activity (34,35,65). In the present study, the ratio of
SERCA2a to monomeric phospholamban was decreased in
senescent myocardium. This index may help estimate the
function of SERCA2a in relation to the inhibitory effect of
phospholamban. Calsequestrin, a Ca21 binding protein located
within the sarcoplasmic reticulum, accounts for the majority of
the sarcoplasmic reticulum’s Ca21 storage capacity (66,67). In
the present study, we found no alteration of calsequestrin
protein content related to age. Others have also reported that
calsequestrin content remains relatively constant between nor-
mal myocardium and dilated cardiomyopathic heart in humans
(55,68,69). Due to its constancy over disease states, calseques-
trin levels have been used to normalize human myocardial
protein levels for purposes of comparison (15). Indeed, in the
present study we report that the ratio of SERCA2a to calse-
questrin was decreased in senescent human myocardium,
which may reflect, in part, the etiology of our functional
results. Therapeutic access to impaired SERCA2a function
may be on the horizon. Investigators have successfully inserted
the gene coding for SERCA2a into rat myocytes via an
adenoviral vector. Not only was the SERCA2a content in-
creased after transfection, it enhanced myocyte relaxation and
decreased resting [Ca21]i levels (70). Similarly, transgenic mice
overexpressing a rat SERCA2 transgene were demonstrated to
have increased SERCA2a mRNA and protein and accelerated
[Ca21]i decline and myocyte relengthening (71).
Our computation of T (tau), the time constant of force
decay, confirmed our results using 2dF/dt to assess diastolic
performance. Simulated I/R resulted in prolongation of relax-
ation in both younger and older myocardium as assessed by
2dF/dt or tau. Furthermore, Ca21 challenge decreased relax-
ation time in younger but not older myocardium. We chose the
monoexponential model to fit the force decay tracings because
of its excellent fit (R . 0.98) to our relaxation data. Others
have proposed more complex mathematical models using
two-sequential exponential (72) or the logistic model (73) in
order to evaluate the isovolumic relaxation pressure time
curve.
Error Discussion. This study should be interpreted with
several important caveats. First, the use of human atrial tissue
as a representative surrogate for myocardial Ca21 handling
proteins may differ from results obtained using ventricular
tissue. Indeed, there may be considerable subcellular differ-
ences between atrial and ventricular myocardium with respect
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to electrophysical processes and even differences between the
stoichiometry of SERCA2a to phospholamban. We chose
atrial tissue because of access. Atrial tissue appears relatively
free of ischemic, restrictive, or myopathic disease, in contrast
to ventricular tissue. We have previously studied human ven-
tricular muscle derived from cardiac transplant recipients; but
were then obligated to concede that we were studying diseased
muscle. Using atrial tissue avoids drawing conclusions about
the response of healthy human myocardium using explanted
cardiomyopathic hearts on high-dose inotropic therapy. We
have previously demonstrated that human ventricular tissue
can be functionally preconditioned (22) and that the protection
is qualitatively similar to atrial preconditioning (23,24). Sec-
ond, although we have demonstrated in this study that there
appeared to be a differential response to I/R and Ca21
handling between younger and older patients, these differences
could have resulted from the presence of concurrent long-term
illnesses, although we found no age-related differences in
concurrent diseases or treatments. Furthermore, hypoxia (sim-
ulated ischemia) was used as a surrogate for ischemia (lack of
blood flow) in the present study because the atrial trabeculae
is not perfused but rather crystalloid superfused during the
experiment. Whether the effects reported by this study on rates
of myocardial contraction and relaxation are limited in relation
to hypoxia versus ischemia remains to be determined.
We thank the cardiothoracic surgical teams for help in obtaining the atrial
samples.
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